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Hepatocyte growth factor: 
New arsenal in the fights against 
renal fibrosis?
Y Liu1 and J Yang2
Hepatocyte growth factor (HGF) has emerged as a potent, endogenous 
antifibrotic factor that shows an impressive efficacy in ameliorating 
tissue fibrosis in a wide variety of animal models. Herrero-Fresneda et 
al. provide new evidence demonstrating that intramuscular injection of 
HGF gene reduces mortality, inflammation, and renal fibrosis in chronic 
allograft nephropathy.
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Aft er injury, tissues in multicellular organ-
isms oft en have a reparative and regen-
erative response in an attempt to repair 
the damaged structure and to restore the 
lost function. An intensive search for the 
substance responsible for triggering liver 
regeneration aft er partial hepatectomy 
led to the disco very of hepatocyte growth 
factor (HGF) about two decades ago.1 In 
retrospect, the name of HGF merely tells 
a small proportion of its function, because 
HGF is widely expressed in many diff er-
ent organs, including the kidney, and 
possesses multiple biological activities. 
Besides its well-described regenerative 
property, studies from numerous labo-
ratories have indicated that HGF is an 
endogenous, antifibrotic factor that is 
capable of ameliorating fi brotic lesions 
and preserving organ functions in a wide 
variety of experimental animal models.2
Herrero-Fresneda and colleagues3 (this 
issue) provide new evidence for a thera-
peutic effect of exogenous HGF in rat 
chronic allograft  nephropathy, a model 
characterized by chronic infl ammation 
and progressive tissue scarring. Delivery 
of human HGF, via intramuscular injec-
tion of its gene, reduces animal mortality, 
inhibits infl ammatory infi ltration, and 
ameliorates renal fi brosis. In the context 
of numerous previous reports,2,4,5 this 
comprehensive study off ers a new affi  r-
mation of a potential utility of HGF as 
a therapeutic agent in combating renal 
fi brotic diseases.
Th e rationale and mechanisms behind 
the benefi cial eff ect of HGF in renal fi bro-
sis appear to be quite compelling (Figure 
1). HGF expression is increased initially 
aft er various insults, perhaps in an eff ort 
to repair the damage. However, chronic 
exposure to injurious stimuli eventually 
leads to the downregulation of HGF, along 
with a progressively increased transform-
ing growth factor-β1 (TGFβ1). As a result, 
the ratio of HGF to TGFβ1 in a chroni-
cally injured tissue is dramatically shift ed 
in favor of a fi brotic milieu. Both HGF and 
TGFβ1 can induce their own expression 
via a positive autoinduction mechanism 
in vivo (Figure 1), and they reciprocally 
inhibit each other. In this regard, supple-
mentation of exogenous HGF would lead 
to a restoration of the balance between 
HGF and TGFβ1 in the diseased kidney, 
thereby eradicating the fi brogenic actions 
of TGFβ1. We have recently carried out 
a series of experiments that offers sig-
nifi cant insights into the mechanisms by 
which HGF antagonizes TGFβ1 action. 
Those studies unravel that HGF effec-
tively intercepts TGFβ1–Smad signaling 
by diverse mechanisms in diff erent types 
of kidney cells.2 HGF inhibits myofi bro-
blastic activation from quiescent intersti-
tial fi broblasts by blocking the activated 
Smad from undergoing nuclear transloca-
tion. In glomerular mesangial cells, HGF 
induces expression of the Smad corepres-
sor TGIF by stabilizing its protein against 
degradation.6 HGF has also been shown to 
block tubular epithelial-to-mesenchymal 
transition by inducing gene expression of 
the Smad corepressor SnoN.7 Collectively, 
HGF is able to antagonize TGFβ–Smad 
signaling in diverse types of kidney cells 
and virtually eliminates the activation of 
fi brogenic cells in the injured kidney.
Th e benefi cial action of HGF in chronic 
kidney diseases may go beyond the inhi-
bition of TGFβ signaling. Th e results of 
Herrero-Fresneda et al.3 as well as those 
from previous reports reveal that HGF 
is able to attenuate renal infi ltration of 
infl ammatory cells in diff erent models 
of chronic kidney diseases.3,8 As infl am-
mation is a major pathologic feature 
that oft en occurs before any signifi cant 
fi brotic lesions, the anti-infl ammatory 
activity of HGF probably represents 
another mechanism leading to amelio-
ration of renal pathologic lesions. HGF 
inhibits the expression of numerous 
proinflammatory cytokines, such as 
tumor necrosis factor-α, interferon-γ, 
monocyte chemoattractant protein-1, 
and interleukin-12b, and blocks infi ltra-
tion of monocytes/macrophages and T 
cells into the kidney.3,8 Emerging evi-
dence suggests that HGF may target 
multiple cells during the diff erent stages 
of infl ammation. For instance, HGF is 
known to potently suppress dendritic-
cell function and downregulate the 
antigen-induced immune response both 
in vivo and in vitro.9 HGF also targets 
vascular endothelial cells by suppressing 
E-selectin expression, thereby attenuat-
ing the E-selectin-mediated monocytic 
adhesion to endothelial monolayers.10 
Finally, HGF inhibits chemokine expres-
sion in kidney parenchymal cells and 
thus decreases chemokine gradient that is 
critical in attracting infl ammatory cells. 
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Th e anti-infl ammatory action of HGF is 
believed to be mediated by its inhibition 
of nuclear factor-κB signaling (Figure 1), 
although the molecular details remain to 
be worked out.
As a regenerative factor, HGF possesses 
a unique ability to promote renal regen-
eration, which could lead to the recovery 
of kidney structure and function after 
chronic injury (Figure 1). Th is implies 
that HGF not only hampers the progres-
sion of renal disease but may potentially 
induce a regression of the established 
renal fi brosis as well. Along this line, it is 
of interest that HGF is capable of modu-
lating matrix remodeling by infl uencing 
the matrix metalloproteinases and their 
inhibitors. In addition, HGF is a sur-
vival factor for tubular epithelial cells by 
inhibiting apoptosis and preferentially 
promotes proliferation of tubular epithe-
lial cells. Th e integration of such diverse 
eff ects would render HGF well suited to 
reconstitute renal parenchyma via regen-
eration aft er injury.
Given its antifibrotic, anti-inflam-
matory, and pro-regenerative proper-
ties (Figure 1), HGF may hold promise 
as a new arsenal in our fights against 
renal fi brotic diseases. Th ere are, how-
ever, several obstacles in translating 
the experimental results into benefit 
for patients in the clinical setting. One 
issue comes from the rapid clearance of 
HGF from the circulation, which makes 
it diffi  cult to sustain a substantial level 
of its protein in vivo. To circumvent 
this problem, one might want to use a 
gene therapy approach to continuously 
produce HGF protein in vivo. Indeed, 
delivery of human HGF gene using a 
hydrodynamics -based strategy results 
in a signifi cant, therapeutically eff ective 
amount of HGF protein in the circulation 
and in the kidney.11 Nonetheless, such a 
gene delivery approach in the present 
form, albeit simple and effi  cient, cannot be 
applicable to humans. It is in this context 
that the study by Herrero-Fresneda et al.3 
is specifi cally interesting. Th e authors used 
a simple, clinically applicable approach, in 
which delivery of HGF gene is achieved by 
intramuscular injection of plasmid vector, 
followed by electroporation. Th e expres-
sion of exogenous human HGF is detect-
able, though low, in the circulation; and, 
importantly, exogenous HGF is obviously 
functional and therapeutically eff ective. 
As judged by the simplicity of the meth-
odology, it appears that this gene delivery 
procedure might be readily adaptable to 
clinical situations.
Th e story of HGF in chronic kidney dis-
eases illustrates how a naturally occurring, 
endogenous regenerative factor helps to 
boost the chronically injured tissue to 
repair and recover. If one considers renal 
fi brosis as a failed wound-healing proc-
ess, supplementation of extra HGF to re-
energize the injured tissue to repair for the 
sake of therapy makes sense. However, the 
role of HGF in renal fi brogenesis is not 
without controversy. At least one report 
indicates that administration of exoge-
nous HGF protein in mice worsens renal 
dysfunction in diabetic nephropathy,12 
although three subsequent, independent 
studies confi rm the benefi cial eff ects of 
HGF on kidney structure and function 
in diabetic animals.5,11,13 Th e reason for 
this discrepancy remains unknown, but it 
suggests that one should be cautious when 
taking HGF to clinical trials.
Our current options for the therapy 
of chronic renal fibrosis are limited, 
despite the introduction of angiotensin-
converting enzyme inhibitors and angio-
tensin receptor blockers into standard 
medical practice in the past decade. HGF 
appears to be able to tackle multiple fac-
ets of the pathology associated with renal 
fi brosis. In addition, combination of HGF 
and anti-angiotensin II therapy results in 
a synergistic eff ect that leads to dramatic 
attenuation of renal fi brotic lesions.14 So, 
is HGF administration, alone or in com-
bination with anti-angiotensin II, a plau-
sible approach to the future treatment of 
the patient with chronic kidney insuf-
fi ciency? A defi nite answer to this ques-
tion, of course, has to await well-designed 
clinical trials.
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Figure 1 | Anti-inflammatory, antifibrotic, and pro-regenerative actions of hepatocyte 
growth factor in chronic kidney disease. Hepatocyte growth factor (HGF) elicits its antifibrotic 
and anti-inflammatory effects by blocking TGFβ–Smad and nuclear factor-κB (NF-κB) signaling. 
By intercepting TGFβ–Smad signaling through diverse mechanisms, HGF inhibits myofibroblastic 
activation from renal interstitial fibroblasts and glomerular mesangial cells and blocks tubular 
epithelial-to-mesenchymal transition (EMT). Both HGF and TGFβ autoinduce themselves in vivo, 
whereas they reciprocally inhibit each other. HGF, via inhibition of NF-κB signaling, also exerts 
an anti-inflammatory activity by blocking inflammatory-cell infiltration and inhibiting cytokine 
expression. In addition, HGF promotes kidney regeneration by accelerating matrix remodeling and 
cell proliferation and inhibiting apoptosis.
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The need for reliable serum 
parathyroid hormone 
measurements
P Ureña Torres1
Serum parathyroid hormone (PTH) is a recognized marker of 
bone remodeling in patients with renal osteodystrophy. However,  
identification of N-terminal truncated PTH fragments and a new form 
of PTH that interfere with second-generation PTH assays  may be 
responsible for the great variability of  PTH values and the difficulties 
of implementing the recommendations of the National Kidney 
Foundation/Kidney Disease Outcomes Quality Initiative.
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Parathyroid hormone (PTH) is a polypep-
tide molecule of 84 amino acids with a 
molecular weight of 9500 daltons. It is 
synthesized by and secreted from the 
chief epithelial cells of parathyroid glands. 
sor molecule called pre-pro-PTH, which 
is encoded by a single gene located on the 
short arm of chromosome 11 (11p15). 
Th is gene has three exons separated by two 
introns; the fi rst exon contains most of the 
5′ non-coding region of the gene, and the 
second exon codes for most of the pre-pro-
PTH sequence. Th e third exon codes for 
three regions: the cleavage site Lys-Arg, 
the mature 1–84 PTH sequence, and the 
untranslated 3′ region.3 Th e mature PTH is 
stocked in secretory granules that fuse with 
the cellular membrane and release PTH in 
response to reduction in the extracellular 
ionized-calcium concentration. Most of 
this PTH is secreted in its intact form, 
1–84; however, it can also be secreted as 
N-terminal truncated fragments or C-ter-
minal fragments aft er intracellular degra-
dation, as in case of hypercalcemia.4 No 
PTH fragment has been found to be the 
result of another gene or alternative splic-
ing of the PTH gene.
Normally, on the basis of the percent-
age of the total immunoreactivity detected 
by diff erent PTH assays, sometimes vali-
dated by the evaluation of PTH molecu-
lar-form concentrations derived from 
high-performance liquid chromatogra-
phy profi les,4 approximately 10%–20% of 
the total circulating PTH molecules are 
in its intact and bioactive form (1–84) 
(Table 1). Indeed, once the secreted 1–84 
PTH reaches the circulation, it is rapidly 
taken up by the liver and the kidney and 
metabolized by several endoproteases in 
two main fragments: N-terminal and C-
terminal fragments (the half-life of the 
entire molecule varies between 2 and 
5 minutes). In the liver, all intact and N-
terminal fragments are metabolized, and 
no N-terminal fragment is released. Th is 
degradation gives rise to several C-termi-
nal fragments, starting from residues at 
positions 34, 37, 41, and 43 and ending 
probably at position 84 or shorter, which 
are oft en released back into the circula-
tion.5,6 Quantitatively, less than 20% of the 
intact PTH is converted into C-terminal 
fragments by the liver. However, because 
of their longer half-life (fi ve to ten times 
longer than that of the intact form) and 
because they are normally cleared by the 
kidneys, those C-terminal PTH frag-
ments represent 80% of the total circulat-
ing PTH molecules in normal individuals 
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Developmentally, there are four orthotopic 
parathyroid glands derived from the pha-
ryngeal pouch; however, supernumerary, 
scanty, and/or ectopic parathyroid glands 
can be seen in a small percentage of sub-
jects.1 Th e formation of these glands is 
under the control of a key regulatory gene 
coding for the transcription factor Gcm-2 
(glial cell missing), which is almost exclu-
sively expressed in these cells.2 PTH is 
synthesized as a 115-amino acid precur-
